 Pliant Therapeutics

Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.

A positive mid-stage trial readout in idiopathic pulmonary fibrosis is powering the biotech's stock higher.

Why Pliant Therapeutics Stock Is Crushing It Today

Pliant Therapeutics (PLRX) stock is rocketing higher on Monday after revealing data from a Phase 2 clinical trial of PLN-74809. The post Why Is Pliant Therapeutics (PLRX) Stock Soaring Today?

Why Is Pliant Therapeutics (PLRX) Stock Soaring Today?

The stock price of Pliant Therapeutics Inc (NASDAQ: PLRX) skyrocketed over 60% pre-market today. This is why.

Pliant Therapeutics (PLRX) Stock: Why It Skyrocketed Over 60% Today

Pliant Therapeutics Inc's (NASDAQ: PLRX) Phase 2a trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF) met its primary and secondary endpoints. The data demonstrated that PLN-74809 was well tolerated over a 12-week treatment period and displayed a favorable.

Why Are Pliant Therapeutics Shares Rallying Today?

Shares of Pliant Therapeutics Inc. PLRX, +1.37% jumped 41.6% in premarket trading on Monday after the company shared positive data from a Phase 2a clinical trial for its experimental idiopathic pulmonary fibrosis treatment. The study, which so far has evaluated 40-, 80-, and 160-milligram doses, met the primary and secondary endpoints.

Pliant's stock gains 41% after sharing positive data about its fibrosis therapy candidate

PLN-74809 demonstrated a dose-dependent treatment effect on FVC and QLF versus placebo over 12 weeks of treatment

Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

SOUTH SAN FRANCISCO, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the presentation of two scientific posters at the International Liver Congress™ (ILC) 2022 of the European Association for the Study of the Liver (EASL), taking place June 22-26, 2022, in London, United Kingdom.

Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial

14 new highs and up 68.36% in the last month. Price target of $38.00 to as high as $51.00.

Pliant Therapeutics: Analysts' Favorite

- IND submission of a novel α7β1 integrin activating allosteric antibody anticipated by year end 2022

Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies

SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the advancement of a fibrosis-directed integrin target into development as part of the Company's 2019 research and development collaboration with Novartis. This initiation of work follows Pliant's successful achievement of target validation under the agreement.

Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration

SOUTH SAN FRANCISCO, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company will present two scientific posters at the International Liver Congress™ 2022 of the European Association for the Study of the Liver (EASL), taking place June 22-26, 2022, in London, United Kingdom.

Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022

Results from the phase 2a INTEGRIS-PSC study using PLN-74809 for the treatment of patients with primary sclerosing cholangitis are expected 1st half of 2023. PLN-74809 is also being explored for the treatment of patients with idiopathic pulmonary fibrosis; Preliminary safety and efficacy data was released in 5 poster presentations at medical conference.

Pliant: Major Catalyst Expected Beginning Of 2023

SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company presented five scientific posters as part of the 2022 American Thoracic Society (ATS) International Conference held May 13-18, 2022, in San Francisco, California.

Pliant Therapeutics Announces Presentations at 2022 American Thoracic Society International Conference

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -1.30% and 12.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Lags Revenue Estimates

$100 million Oxford loan facility extends cash runway to mid-2024

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

Up to $100 million of non-dilutive capital from Oxford Finance LLC

Pliant Therapeutics Enters into $100 million Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809

SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics (NASDAQ: PLRX) announced today that PLN-74809, its oral, dual-selective αvß6/αvß1 integrin inhibitor, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of idiopathic pulmonary fibrosis (IPF). PLN-74809, the Company's lead drug candidate, is currently being tested as part of the INTEGRIS-IPF Phase 2a clinical trial (NCT04396756). Pliant anticipates topline data from this randomized, double-blind, placebo-controlled trial in patients with IPF, in mid-2022.

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis

Five posters include data across biomarker, target engagement, and mechanism studies supporting development of PLN-74809, a dual-selective inhibitor of αvβ6/αvβ1 integrins, in IPF

Pliant Therapeutics Announces Multiple Presentations at the 2022 American Thoracic Society International Conference

Pliant Therapeutics Inc (NASDAQ: PLRX) says that with just two FDA-approved Idiopathic Pulmonary Fibrosis drugs, it believes that is a high unmet need. Roche Holdings AG's (OTC: RHHBY) Esbriet and Boehringer Ingelheim's Ofev have around $4 billion combined U.S. sales.

Read Why Pliant Therapeutics Shares Are Soaring Today

SOUTH SAN FRANCISCO, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliant's President and Chief Executive Officer, will participate in a fireside chat as part of the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022, at 2:15 p.m. ET.

Pliant Therapeutics to Participate in Needham Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Monday, February 28th by Pliant Therapeutics, Inc. (Nasdaq: PLRX), please note that in the Condensed Statements of Operations table, the Year Ended 2021 value was missing from the Research and development line and the corresponding totals were understated by the omitted value. The corrected release follows:

CORRECTION - Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 10.53% and 45.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Lags Revenue Estimates

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported fourth quarter and full year 2021 financial results.

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

At all dose levels, PLN-74809 demonstrated durable pSmad suppression relative to placebo at 6 hours and 24 hours TGF-β suppression of up to 92% and 76% from baseline at 6 and 24 hours, respectively PLN-74809 was well tolerated with no serious or severe adverse events

Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-β Signaling in Healthy Volunteers

Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-IPF Phase 2a trial continue without modification and proceed to evaluate dosing at 320mg

Pliant Therapeutics Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

News for Pliant Therapeutics Stock (PLRX)